Nuvation Bio Inc. Class A (NUVB)
NYSE: NUVBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NUVB stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.34B
- EPS (TTM)
- -$0.39
- Dividend yield
- None
- 52-week range
- 3.71 – 9.75
- Day range
- 3.72 – 3.91
- Volume / Avg
- 6.85M / 5.24M
- Beta
- —
- Shares outstanding
- 352.02M
52-week range
NUVB stock today
Nuvation Bio (NUVB) closed at $3.80 on Nov 20, down 0.26% (-$0.01), versus the S&P 500's 3.70% decline. Shares are 61.0% below their 52-week high of $9.75, set on Dec 22, 2025 and 2.4% above the 52-week low of $3.71, near the bottom of the past year's range. NUVB is down 57.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 45.6%.
Nuvation Bio has posted a net loss over the last twelve months (EPS of -$0.39), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Nuvation Bio
Company profileNuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. David T. Hung M.D.
- Headquarters
- New York, NY
- Employees
- 310
- IPO year
- 2020
- Website
- nuvationbio.com
Financial highlights
Full financialsIn fiscal 2025, Nuvation Bio generated $62.9 million in revenue, up 699.0% from fiscal 2024, its 2nd consecutive year of revenue growth. Nuvation Bio reported a net loss of $204.6 million, compared with a loss of $567.9 million a year earlier. Operating margin was -338.7%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $62.90M | $7.87M | $0 | — | — |
| Growth | +698.96% | — | — | — | — |
| Net income | $-204.63M | $-567.94M | $-75.80M | $-104.20M | $-86.85M |
| EPS (diluted) | $-0.60 | $-2.11 | $-0.35 | $-0.48 | $-0.44 |
Analyst forecast
ForecastConsensus (13 analysts)
strong_buy
Avg. price target
$12.45+227.63%
- Strong buy 3
- Buy 9
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $-0.16 vs $-0.11
- Surprise
- -45.45%
NUVB news
All NUVB news- Nuvation Bio to Present at the Jefferies Global Healthcare Conference in LondonPR Newswire
- Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business UpdatePR Newswire
- Jazz Pharmaceuticals (JAZZ) Reports Q3 Loss, Tops Revenue EstimatesNasdaqJAZZ, NUVB
- Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026PR Newswire
Nuvation Bio peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NBTXNanobiotix S.A. ADR | 26.50 | -2.98% | $1.35B | vs NUVB |
| PAHCPhibro Animal Health Corporation Class A | 33.29 | -2.32% | $1.35B | vs NUVB |
| URGNUroGen Pharma Ltd. | 27.65 | -12.86% | $1.36B | vs NUVB |
| QUREuniQure N.V. | 19.35 | -4.35% | $1.36B | vs NUVB |
| RAPPRapport Therapeutics Inc. | 23.16 | -1.82% | $1.37B | vs NUVB |
| INVAInnoviva Inc. | 18.41 | 0.00% | $1.31B | vs NUVB |
| ANABAnaptysBio Inc. | 46.63 | -1.62% | $1.39B | vs NUVB |
| TYRATyra Biosciences Inc. | 20.12 | +1.98% | $1.39B | vs NUVB |
Indexes, lists and sector
Nuvation Bio stock FAQ
What is Nuvation Bio's stock price today?
NUVB last traded at $3.80 as of Nov 20, 4:00 PM EST, down 0.26% on the day. Prices are delayed at least 15 minutes.
Who is Nuvation Bio's CEO?
Dr. David T. Hung M.D. is the chief executive officer of Nuvation Bio Inc. Class A, which has about 310 employees.
What is the NUVB 52-week high?
The 52-week high for NUVB is $9.75 and the 52-week low is $3.71. The stock is currently 61.0% below its high.